16 February 2021 - successful test results
The AIM-listed group which focuses on novel cancer immunotherapies and diagnostics has revealed that clinical studies have revealed an excellent performance from its COVID-19 rapid antigen test. This has correctly revealed that all those who tested negative for COVID in its tests were indeed negative with this 100% success rate clearly vital if the test is to be used in mass screening. The company will now move to a full clinical validation with a larger number of samples, with a view to bringing the test to market around the end of March . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
